CAJ | 학술논문

随着对手性药物认识不断深入和不对称合成技术、拆分技术的发展，手性药物市场逐年扩大，手性药物已经成为新分子实体研究开发的重要方向，质子泵抑制剂（ PPI）的光学异构体也陆续获得批准上市。本文主要就PPI光学异构体的药理毒理内容和现阶段的注册申请评价思路进行讨论。
수착대수성약물인식불단심입화불대칭합성기술、탁분기술적발전，수성약물시장축년확대，수성약물이경성위신분자실체연구개발적중요방향，질자빙억제제（ PPI）적광학이구체야륙속획득비준상시。본문주요취PPI광학이구체적약리독리내용화현계단적주책신청평개사로진행토론。
With the deepening knowledge about chiral drugs and the de-velopment of asymmetric synthesis technology as well as splitting technol-ogy, chiral drug market has gradually expanded , and chiral drugs have led us to an important direction to study and develop new molecular enti-ties.Proton pump inhibitor ( PPI) optical isomers are approved to be on the market in succession.The article discusses pharmacodynamics , phar-macokinetics and safety assessment about the application for registration issues which of the PPI optical isomers mainly .